Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Although you might be used to kids walking from doorbell to doorbell every Halloween, in recent years, that tradition has been upstaged by a new one: trunk-or-treat. Rather than knocking on ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Jascayd is the first new IPF therapy approved in over 10 years, addressing a rare and serious disease with limited treatments. FDA approval was based on Phase III trials showing reduced FVC decline ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...

Halloween is just around the corner, and communities across the area are getting ready to welcome little ghosts, goblins, superheroes, and princesses for trick-or-treat fun. Families can find a ...

Halloween is here, which means it's time for trunk-or-treating. Numerous businesses and organizations around Louisville are hosting truck-or-treating events, an alternative to traditional ...

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

Sotatercept reduced patient’s risk of deterioration by 76% due to pulmonary hypertension, or high blood pressure in the heart-to-lung system, researchers reported recently in the New England Journal ...